Miglustat therapy in juvenile Sandhoff disease

Journal of Inherited Metabolic Disease

Volumn 32, Issue SUPPL. 1, 2009, Pages

  Tallaksen, C M E ^a,b   Berg, J E ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LOVISENBERG DIAKONALE HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; BETA N ACETYLHEXOSAMINIDASE BETA CHAIN; CERAMIDE GLUCOSYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSYLTRANSFERASE; HEXB PROTEIN, HUMAN; MIGLUSTAT;

ADOLESCENT; ARTICLE; CASE REPORT; CEREBELLUM; DEPRESSION; DISEASE COURSE; DRUG ANTAGONISM; ELECTROCONVULSIVE THERAPY; GENETICS; HUMAN; MALE; MUTATION; PATHOLOGY; PRESCHOOL CHILD; SANDHOFF DISEASE;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; BETA-HEXOSAMINIDASE BETA CHAIN; CEREBELLUM; CHILD, PRESCHOOL; DEPRESSION; DISEASE PROGRESSION; ELECTROCONVULSIVE THERAPY; ENZYME INHIBITORS; GLUCOSYLTRANSFERASES; HUMANS; MALE; MUTATION; SANDHOFF DISEASE;

EID: 84880990833     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1224-7     Document Type: Article

References (15)

1. 2 gangliosidosis. J Inherit Metab Dis 29(Suppl 1):S160
2. Hendriksz CJ, Corry PC, Wraith JE, Besley GT, Cooper A, Ferrie CD (2004) Juvenile Sandhoff disease - nine new cases and a review of the literature. J Inherit Metab Dis 27:241-249 (Pubitemid 38756340)
3. Jeyakumar M, Butters TD, Cortina-Borja M et al. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 96:6388-6393 (Pubitemid 29256675)
4. Jeyakumar M, Smith DA, Williams IM et al. (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56:642-649 (Pubitemid 39540744)
5. Lachmann RH, Wright N, Parker A et al. (2006) Substrate reduction therapy in Sandhoff disease: evidence for improvement in nervous function in patients treated with miglustat. J Inherit Metab Dis 29(Suppl 1):130
6. 2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 118:e1550-1562
7. 2 gangliosidosis. Mol Genet Metab 96(1-2):215-224
8. 2 gangliosidosis. Mol Genet Metab 97(4):284-291
9. 2 gangliosidosis. Biochim Biophys Acta 1096:87-94
10. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249-254 (Pubitemid 29058114)
11. Platt FM, Neises GR, Dwek RA, Butters TD (1994) N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269:8362-8365
12. Platt FM, Neises GR, Reinkensmeier G et al. (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276:428-431 (Pubitemid 27180707)
13. Poloni M, Patrini C, Rocchelli B, Rindi G (1982) Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis. Arch Neurol 39:507-509 (Pubitemid 12089652)
14. 2 gangliosidosis: clinical and enzymatic heterogeneity. Neurology 40:145-150
15. Treiber A, Morand O, Clozel M (2007) The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 37:298-314 (Pubitemid 46439676)